Low-dose Rituximab and High-dose Dexamethasone as First Line Treatment for ITP

Sponsor
Hospital Universitario Dr. Jose E. Gonzalez
Study ID
NCT01107951
Phase
PHASE2
Status
Completed

Conditions

  • Immune Thrombocytopenic Purpura

Eligibility Criteria

Sex
ALL
Age
18 Years - 85 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to determine the response rate and response duration with the combination of low-dose rituximab and high-dose dexamethasone in the treatment of adult immune thrombocytopenic purpura.

Key Dates

Start date
Apr 30, 2010
Status verified
Mar 2013
Primary completion
Apr 30, 2010
Completion
Jan 31, 2013

Study Design

Enrollment
21 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Other: Rituximab -dexamethasone
    only one arm receive four doses weekly rituximab and four dosis daily dexamethasona

Primary Outcome Measure

Number of patients with sustained response after 6 months [ Time Frame: 6 months ]

Related Studies